A Study of Tobramycin Inhalation Powder From a Modified Manufacturing Process Versus Placebo
- Conditions
- Cystic Fibrosis
- Interventions
- Drug: Placebo
- First Posted Date
- 2009-06-11
- Last Posted Date
- 2012-10-03
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 62
- Registration Number
- NCT00918957
- Locations
- 🇷🇺
Novartis Investigator Site, Yaroslavi, Russian Federation
🇿🇦Novartis Investigative Site, Durban, South Africa
Safety/Tolerability, Pharmacokinetics/Pharmacodynamics (PK/PD) of LCZ696 in Patients With Stable Heart Failure
- First Posted Date
- 2009-06-04
- Last Posted Date
- 2020-12-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 30
- Registration Number
- NCT00913653
- Locations
- 🇷🇺
GOUVPO Russian Peoples´ Friendship University, Center of Applied, Moscow, Russian Federation
A Trial Evaluating the Effects of Zoledronic Acid 5 mg Infusion on Bone Mineral Density (BMD) in Postmenopausal Osteoporosis (PMO) Patients Between the Ages of 50 and 65 Years
- First Posted Date
- 2009-05-29
- Last Posted Date
- 2017-03-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 118
- Registration Number
- NCT00909961
- Locations
- 🇹🇷
Novartis Investigative site, Konya, Turkey
🇹🇷Novartis Investigational site, Istanbul, Turkey
Efficacy, Tolerability, and Comfort of 0.3% Hypromellose Eyedrops in Patients Undergoing LASIK Surgery
- Conditions
- Dry Eye
- Interventions
- First Posted Date
- 2009-05-28
- Last Posted Date
- 2020-08-17
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 170
- Registration Number
- NCT00909324
- Locations
- 🇮🇳
Novartis Investigative Site, Delhi, India
Pharmacokinetics and Safety of Single-Dose Telbivudine in Children and Adolescents With Chronic Hepatitis B
- Conditions
- Chronic Hepatitis B
- Interventions
- Drug: LDT600 (Telbivudine)
- First Posted Date
- 2009-05-25
- Last Posted Date
- 2020-12-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 22
- Registration Number
- NCT00907894
- Locations
- 🇧🇪
Novartis Investigative Site, Brussels, Belgium
🇬🇧Novartis Investigator Site, Birmingham, United Kingdom
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of APL180
- First Posted Date
- 2009-05-25
- Last Posted Date
- 2009-11-20
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 104
- Registration Number
- NCT00907998
- Locations
- 🇺🇸
Icon Clinical Research, San Antonio, Texas, United States
🇳🇱Novartis Investigator Site, Amsterdam, Netherlands
🇺🇸Pinnacle Research Group, Anniston, Alabama, United States
Nilotinib in Adult Patients With Imatinib-resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase
- Conditions
- Chronic Myeloid Leukemia
- First Posted Date
- 2009-05-20
- Last Posted Date
- 2012-07-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT00905593
- Locations
- 🇲🇽
Novartis Investigative Site, Mexico City, Mexico
Efficacy and Safety Comparison of RAD001 Versus Sunitinib in the First-line and Second-line Treatment of Patients With Metastatic Renal Cell Carcinoma
- First Posted Date
- 2009-05-18
- Last Posted Date
- 2016-11-08
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 471
- Registration Number
- NCT00903175
- Locations
- 🇺🇸
University of California at Los Angeles Dept. of UCLA (3), Los Angeles, California, United States
🇺🇸Loyola University Medical Center /Cardinal Bernardin Cancer Cardinal Bernardin Cancer (3), Maywood, Illinois, United States
🇺🇸Billings Clinic Dept of Billings Clinic(2), Billings, Montana, United States
Valsartan Intensified Primary Care Reduction of Blood Pressure Study
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2009-05-15
- Last Posted Date
- 2012-12-04
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 2337
- Registration Number
- NCT00902304
- Locations
- 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
🇦🇺Professor Simon Stewart-Principal Investigator, Melbourne, Australia
🇦🇺Professor Garry Jennings-Co Principal Investigator, Melbourne, Australia
Imatinib (QTI571) in Pulmonary Arterial Hypertension
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Drug: Placebo
- First Posted Date
- 2009-05-15
- Last Posted Date
- 2016-02-17
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 202
- Registration Number
- NCT00902174
- Locations
- 🇬🇧
Novartis Investigative Site, Sheffield, United Kingdom
🇨🇭University Hospital Basel, Basel, Switzerland
🇪🇸Novartis investigative site, Valencia, Spain